TITLE:
Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions
AUTHORS:
Jan M. Kitzen, Joseph V. Pergolizzi Jr., Robert Taylor Jr., Robert B. Raffa
KEYWORDS:
Crisaborole, Apremilast, Phosphodiesterase, PDE4, Inflammation, Cytokines, Interleukins, cAMP
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.9 No.9,
September
10,
2018
ABSTRACT: Two
selective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®,
Pfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United
States Food and Drug Administration for the treatment of related but different
dermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis,
respectively). The purpose of this review is to summarize the underlying
biochemistry and pathophysiology associated with these dermatologic conditions,
review the chemistry, pharmacology and safety of each of these products, and
present preclinical and clinical evidence that may help explain why these two
PDE4 inhibitors offer new treatment options for these skin conditions.